DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Gelber RD, Goldhirsch A, Piccart M et al.
HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in
women with HER2-positive early breast cancer at 8 years of median follow up.
ESMO Congress 2012; Abstract LBA6: presented October 1; 2012.
We do not assume any responsibility for the contents of the web pages of other providers.